News - Kyowa Hakko Kirin, saxagliptin


Popular Filters

1 to 25 of 33 results

Kyowa Hakko drops Ph II study of bardoxolone


Japanese drugmaker Kyowa Hakko Kirin says it is discontinuing its Phase II clinical studies evaluating…

DiabetesKyowa Hakko KirinNephrology and HepatologyPharmaceuticalReata PharmaceuticalsResearch

AstraZeneca advances Medimmune’s benralizumab to Phase III in severe asthma

AstraZeneca advances Medimmune’s benralizumab to Phase III in severe asthma


AstraZeneca has started the Phase III Windward program for benralizumab, a potential treatment for severe…

AstraZenecaEuropeKyowa Hakko KirinMedImmunePharmaceuticalResearchRespiratory and Pulmonary

ProStrakan initiates EU launch of Sancuso


ProStrakan has started the European Union roll-out of its transdermal patch Sancuso for the prevention…

BiotechnologyEuropeKyowa Hakko KirinLicensingOncologyProStrakanSancuso

Kyowa Hakko establishes translation research lab in Singapore


Japanese mid-sized drugmaker Kyowa Hakko Kirin (TYO: 41521) has established an international R&D center…

Asia-PacificKyowa Hakko KirinPharmaceuticalResearch

Kyowa Hakko Kirin collaborates with Ultragenyx on KRN23


Japanese mid-sized drugmaker Kyowa Hakko Kirin (TYO: 4151) has entered into a collaboration and license…

BiotechnologyKRN23Kyowa Hakko KirinLicensingPharmaceuticalRare diseasesResearchUltragenyx

Japan briefs: Kyowa Kirin debuts Onglyza; Otsuka enrolls TB study, sets up new European


Japanese drugmaker Kyowa Hakko Kirin (TY: 4151) revealed that it launched the type 2 diabetes drug Onglyza…

Asia-PacificdelamanidEuropeKyowa Hakko KirinMarkets & MarketingOnglyzaOtsukaPharmaceuticalResearch

Kyowa Hakko launches PD drug Nouriast and files for additional indication of fluorouracil in Japan


Japanese drugmaker Kyowa Hakko Kirin (TYO: 4151) say that it launched its novel Parkinson's disease drug…

Asia-PacificfluorouracilKyowa Hakko KirinMarkets & MarketingNeurologicalNouriastOncologyPharmaceuticalRegulation

Kyowa Hakko set to file for pegfilgrastim approval in Japan following strong Ph III data


Mid-size Japanese drugmaker Kyowa Hakko Kirin (TYO: 4151) on Friday released positive top-line results…

Asia-PacificBiotechnologyKyowa Hakko KirinOncologypegfilgrastimPharmaceuticalRegulationResearch

Drug discovery alliances for Boehringer and Horizon Discovery; and NovAliX with Kyowa Hakko


UK-based Horizon Discovery, a provider of research tools to support the development of personalized medicines,…

Boehringer IngelheimHorizon DiscoveryKyowa Hakko KirinLicensingNovAliXOncologyPharmaceuticalResearch

Kyowa Hakko files for additional indications for Leunase


Japanese drugmaker Kyowa Hakko Kirin (TYO: 4151) says that it has filed an application based on evidence…

Asia-PacificKyowa Hakko KirinLeunaseOncologyPharmaceuticalRegulation

ProStrakan buys GTx' US rights to breast cancer drug Fareston


Scotland-based ProStrakan, a subsidiary of Japanese drugmaker Kyowa Hakko Kirin (TYO: 4151), has acquired…

FarestonGTxKyowa Hakko KirinMarkets & MarketingOncologyOrion PharmaPharmaceuticalProStrakan

Kyowa Hakko Kirin returns rights to Busulfex to Otsuka


Japanese drugmaker Kyowa Hakko Kirin (TYO: 4151) has reached agreement on returning development and marketing…

BusulfexKyowa Hakko KirinLicensingOncologyOtsukaPharmaceutical

Japan's drug majors post mixed financial results


Japan's leading drugmakers rolled out financial results for the first fiscal quarter of 2013, ended June…

Daiichi SankyoDainippon Sumitomo PharmaFinancialKyowa Hakko KirinPharmaceuticalTakeda Pharmaceuticals

Otsuka sells on Japanese saxagliptin rights to Kyowa Hakko


Japanese drugmakers Otsuka Pharmaceutical (TYO: 4578) and Kyowa Hakko Kirin (TYO: 4151) have entered…

Asia-PacificBristol-Myers SquibbDiabetesKyowa Hakko KirinLicensingOncologyOtsukaPharmaceuticalResearchsaxagliptin

1 to 25 of 33 results

Back to top